The burden of rheumatoid arthritis and access to treatment: Health burden and costs

European Journal of Health Economics

Volumn 8, Issue SUPPL. 8, 2008, Pages

  Lundkvist, J ^a   Kastang F ^a   Kobelt, G ^b  

^a i3 Innovus   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cost; Health burden; Rheumatoid arthritis

Indexed keywords

ARTICLE; HEALTH CARE ACCESS; HEALTH CARE COST; PREVALENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RHEUMATOID ARTHRITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST OF ILLNESS; HEALTH CARE COSTS; HEALTH SERVICES ACCESSIBILITY; HUMANS; MODELS, ECONOMIC; PILOT PROJECTS; QUALITY-ADJUSTED LIFE YEARS; WORLD HEALTH;

EID: 38449083553     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-007-0088-8     Document Type: Article

References (74)

1. Silman, A.: Epidemiology of rheumatic diseases. Oxford University Press, Oxford (1993)
2. Centers for Disease Control and Prevention: Prevalence of arthritis-US 1997. MMWR 50, 334-336, [CD] (2001)
3. Guillemin, F., Saraux, A., Guggenbuhl, P., et al.: Prevalence of rheumatoid arthritis in France: 2001. Ann. Rheum. Dis. 64, 1427-1430 (2005)
4. Alamanos, Y., Voulgari, P.V., Drosos, A.A.: Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology Criteria: a systematic review. Semin. Arthritis Rheum. 36, 182-188 (2006)
5. Andrianakos, A., Trontzas, P., Christoyannis, F., et al.: Prevalence of rheumatic diseases in Greece: a cross-sectional population-based epidemiological study. The ESORDIG Study. J. Rheumatol. 30, 1589-1601 (2003)
6. Carmona, L., Villaverde, V., Hernandez-Garcia, C., et al.: The prevalence of rheumatoid arthritis in the general population of Spain. Rheumatology (Oxford) 41(1), 88-95 (2002)
7. Cimmino, M.A., Parisi, M., Moggiana, G., et al.: Prevalence of rheumatoid arthritis in Italy: the Chiavari Study. Ann. Rheum. Dis. 57, 315-318 (1998)
8. Drosos, A.A., Alamanos, I., Voulgari, P.V., et al.: Epidemiology of adult rheumatoid arthritis in northwest Greece 1987-1995. J. Rheumatol. 24, 2129-2133 (1997)
9. Saraux, A., Guedes, C., Allain, J., et al.: Prevalence of rheumatoid arthritis and spondyloarthropathy in Brittany, France. Societe de Rhumatologie de l'Ouest J. Rheumatol. 26, 2622-2627 (1999)
10. Gabriel, S.E., Crowson, C.S., O'Fallon, W.M.: The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955-1985. Arthritis Rheum. 42, 415-420 (1999)
11. Hakala, M., Pollanen, R., Nieminen, P.: The ARA 1987 revised criteria select patients with clinical rheumatoid arthritis from a population based cohort of subjects with chronic rheumatic diseases registered for drug reimbursement. J. Rheumatol. 20, 1674-1678 (1993)
12. Power, D., Codd, M., Ivers, L., et al.: Prevalence of rheumatoid arthritis in Dublin, Ireland: a population based survey. Ir. J. Med. Sci. 168, 197-200 (1999)
13. Riise, T., Jacobsen, B.K., Gran, J.T.: Incidence and prevalence of rheumatoid arthritis in the county of Tromsö, northern Norway. J. Rheumatol. 27, 1386-1389 (2000)
14. Simonsson, M., Bergman, S., Jacobsson, L.T., et al.: The prevalence of rheumatoid arthritis in Sweden. Scand. J. Rheumatol. 28, 340-343 (1999)
15. Symmons, D., Turner, G., Webb, R., et al.: The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology (Oxford) 41, 793-800 (2002)
16. Uhlig, T., Kvien, T.K., Glennas, A., et al.: The incidence and severity of rheumatoid arthritis, results from a county register in Oslo, Norway. J, Rheumatol, 25, 1078-1084 (1998)
17. Rasch, E., Hirsch, R., Paulose-Ram, R., Hochberg, M.: Prevalence of rheumatoid arthritis in persons 60 years of age and older in the United States: effect of different methods of case classification. Arthritis Rheum. 48, 917-926 (2003)
18. Drosos, A., et al.: Rheumatoid Arthritis in Greek and British patients: a comparative clinical, radiologic, and serologic study. Arthritis Rheum. 35, 745-748 (1992)
19. Antoni, C., Maini, R., Grunke, M., et al.: Cooperative of QoL in Rheumatic disease: results of a survey among 6,000 patients across 11 European countries. Arthritis Rheum 46:ACR (abstract) (2002)
20. WHO Death and DALY estimates for 2002 by cause for WHO Member States, http://www.who.int/healthinfo/statistics/bodgbddeathdalyestimates.xls
21. Rupp, I., Boshuizen, H.C., Dinant, H.J., et al.: Disability and health-related quality of life among patients with rheumatoid arthritis: association with radiographic joint damage, disease activity, pain, and depressive symptoms. Scand. J. Rheumatol. 35, 175-181 (2006)
22. Young, A., Wilkinson, P., Talamo, J., et al.: Socioeconomic deprivation and rheumatoid disease. What lessons for the health service? Ann. Rheum. Dis. 59, 794-799 (2000)
23. Kobelt, G., Lindgren, P., Lindroth, Y., Jacobson, L., Eberhardt, K.: Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis. Rheumatology (Oxford) 44, 1169-1175 (2005)
24. Kobelt, G., Richard, B., Peeters, P., Sany, J.: Costs and quality of life of patients with RA in France. ACR 2006, Bone Joint Spine 75(7), (2008)
25. Currie, C.J., McEwan, P., Peters, J.R., Patel, T.C., Dixon, S.: The routine collation of health outcomes data from hospital-treated subjects in the Health Outcomes Data Repository (HODaR): descriptive analysis from the first 20,000 subjects. Value Health 8, 581-590 (2005)
26. Orme, M., Kerrigan, J., Tyas, D., Russell, N., Nixon, R.: The effect of disease, functional status and relapses ont he utility of people with multiple sclerosis in the UK. Value Health 10, 54-60 (2007)
27. Bloom, B.S., Bruno, D.J., Maman, D.Y., Jayadevappa, R.: Usefulness of US cost-of-illness studies in healthcare decision making. Pharmacoeconomics 19, 207-213 (2001)
28. Koopmanschap, M.A.: Cost-of-illness studies. Useful for health policy? Pharmacoeconomics 14, 143-148 (1998)
29. Cooper, N.J.: Economic burden of rheumatoid arthritis: a systematic review. Rheumatology (Oxford) 39, 28-33 (2000)
30. Pugner, K.M., Scott, D.I., Holmes, J.W., Hieke, K.: The costs of rheumatoid arthritis: an international long-term view. Semin. Arthritis Rheum. 29, 305-220 (2000)
31. Rosery, H., Bergemann, R., Maxion-Bergemann, S.: International variation in resource utilisation and treatment costs for rheumatoid arthritis: a systematic literature review. Pharmacoeconomics 23, 243-257 (2005)
32. Huscher, D., Merkesdal, S., Thiele, K., et al.: Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann. Rheum. Dis. 65, 1175-1183 (2006)
33. Kirwan, J.R.: Conceptual issues in scoring radiographic progression in rheumatoid arthritis. J. Rheumatol. 26, 720-725 (1999)
34. Landewe, R.B., Boers, M., Verhoeven, A.C., et al.: COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum. 46, 347-356 (2002)
35. Kobelt, G., Jonsson, L., Lindgren, P., et al.: Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis. Arthritis Rheum. 46, 2310-2319 (2002)
36. Verstappen, S.M., Verkleij, H., Bijlsma, J.W., et al.: Determinants of direct costs in Dutch rheumatoid arthritis patients. Ann. Rheum. Dis. 63, 817-824 (2004)
37. Hallert, E., Husberg, M., Skogh, T.: Costs and course of disease and function in early rheumatoid arthritis: a 3-year follow-up (the Swedish TIRA project). Rheumatology (Oxford) 45, 325-331 (2006)
38. Michaud, K., Messer, J., Choi, H.K., Wolfe, F.: Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. Arthritis Rheum. 48, 2750-2762 (2003)
39. Kobelt, G., Eberhardt, K., Jonsson, L., Jonsson, B.: Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum. 42, 347-356 (1999)
40. Hulsemann, J.L., Ruof, J., Zeidler, H., Mittendorf, T.: Costs in rheumatology: results and lessons learned from the 'Hannover Costing Study'. Rheumatol. Int. 26, 704-711 (2006)
41. Lajas, C., Abasolo, L., Bellajdel, B., et al.: Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study. Arthritis Rheum. 49, 64-70 (2003)
42. Albers, J.M., Kuper, H.H., van Riel, P.L., et al.: Socio-economic consequences of rheumatoid arthritis in the first years of the disease. Rheumatology (Oxford) 38, 423-430 (1999)
43. Merkesdal, S., Ruof, J., Schoffski, O., et al.: Indirect medical costs in early rheumatoid arthritis: composition of and changes in indirect costs within the first three years of disease. Arthritis Rheum. 44, 528-534 (2001)
44. Young, A., Dixey, J., Cox, N., et al.: How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the Early RA Study (ERAS). Rheumatology (Oxford) 39, 603-611 (2000)
45. Fex, E., Larsson, B-M., Nived, K., Eberhardt, K.: Impact of rheumatoid arthritis on work status and social and leisure time activities in patients followed 8 years from onset. J. Rheumatol. 25, 44-50 (1997)
46. Merkesdal, S., Huelsemann, J.L., Mittendorf, T., et al.: Productivity costs of rhumatoid arthritis in Germany: cost composition and prediction of main cost components (in German). Z. Rheumatol. 65, 527-534 (2006)
47. Chorus, A.M., Miedema, H.S., Wevers, C.J., van Der Linden, S.: Labour force participation among patients with rheumatoid arthritis. Ann. Rheum. Dis. 59, 549-554 (2000)
48. Young, A., Dixey, J., Kulinskaya, E., et al.: Which patients with early RA stop working? Results from a 5-year inception cohort of 547 patients. Ann. Rheum. Dis. 61, 335-340 (2002)
49. Meenan, R.F., Yelin, E.H., Henke, C.J., et al.: The costs of rheumatoid arthritis. A patient-oriented study of chronic disease costs. Arthritis Rheum. 21, 827-833 (1978)
50. Liang, M.H., Larson, M., Thompson, M., et al.: Costs and outcomes in rheumatoid arthritis and osteoarthritis. Arthritis Rheum. 27, 522-529 (1984)
51. Lubeck, D.P., Spitz, P.W., Fries, J.F., et al.: A multicenter study of annual health service utilization and costs in rheumatoid arthritis. Arthritis Rheum. 29, 488-493 (1986)
52. Wolfe, F., Kleinheksel, S.M., Spitz, P.W., et al.: A multicenter study of hospitalization in rheumatoid arthritis. Frequency, medical-surgical admissions, and charges. Arthritis Rheum. 29, 614-619 (1986)
53. Bloom, B.S.: Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis. Am. J. Med. 84, 20-24 (1988)
54. Gabriel, S.E., Crowson, C.S., Campion, M.E., O'Fallon, W.M.: Direct medical costs unique to people with arthritis. J. Rheumatol. 24, 719-725 (1997)
55. Gabriel, S.E., Crowson, C.S., Campion, M.E., O'Fallon, W.M.: Indirect and nonmedical costs among people with rheumatoid arthritis and osteoarthritis compared with nonarthritic controls. J. Rheumatol. 24, 43-48 (1997)
56. Lanes, S.F., Lanza, L.L., Radensky, P.W., et al.: Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting: the importance of drug and surgery costs. Arthritis Rheum. 40, 1475-1481 (1997)
57. Ward, M.M., Javitz, H.S., Yelin, E.H.: The direct cost of rheumatoid arthritis. Value Health 3, 243-252 (2000)
58. Yelin, E.: The costs of rheumatoid arthritis: absolute, incremental, and marginal estimates. J. Rheumatol. 44 (Suppl), 47-51 (1996)
59. Yelin, E., Wanke, L.A.: An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum. 42, 1209-1218 (1999)
60. Andlin-Sobocki, P., Jonsson, B., Wittchen, H.U., Olesen, J.: Cost of disorders of the brain in Europe. Eur. J. Neurol. 12(Suppl 1), 1-27 (2005)
61. OECD health data (2006) OECD Geneva
62. Eurostat (2006) Economy and finance, Brussels
63. The Word Bank (2007) http://www.worldbank.org
64. Kobelt, G., Berg, J., Lindgren, P., Fredrikson, S., Jönsson, B.: Costs and quality of life of multiple sclerosis in Europe. J. Neurol. Neurosurg. Psychiatry 77, 918-926 (2006)
65. Wagner, E., Lackerbauer, E., Siegmeth, W.: Direct and indirect costs of rheumatoid arthritis and the socio-emotional effects of this disease-an Austrian study (in German). Wien Med Wochenschr 155, 217-226 (2005)
66. Westhovens, R., Boonen, A., Verbruggen, L., et al.: Healthcare consumption and direct costs of rheumatoid arthritis in Belgium. Clin. Rheumatol. 24, 615-619 (2005)
67. Maetzel, A., Li, L.C., Pencharz, J., et al.: The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study. Ann. Rheum. Dis. 63, 395-401 (2004)
68. Sorensen, J.: Health care costs attributable to the treatment of rheumatoid arthritis. Scand. J. Rheumatol. 33, 399-404 (2004)
69. Leardini, G., Salaffi, F., Montanelli, R., et al.: A multicenter cost-of-illness study on rheumatoid arthritis in Italy. Clin. Exp. Rheumatol. 20, 505-515 (2002)
70. Verstappen, S.M., Jacobs, J.W., van der Heijde, D.M., et al.: Utility and direct costs: ankylosing spondylitis compared with rheumatoid arthritis. Ann. Rheum. Dis. (2006)
71. Jacobsson, L.T., Lindroth, Y., Marsal, L., Juran, E., Bergstrom, U., Kobelt, G.: Rheumatoid arthritis: what does it cost and what factors are driving those costs? Results of a survey in a community-derived population in Malmo, Sweden. Scand. J. Rheumatol. 36, 179-183 (2007)
72. Kobelt, G., Lindgren, P., Singh, A., Klareskog, L.: Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial. Ann. Rheum. Dis. 64, 1174-1179 (2005)
73. McIntosh, E.: The cost of rheumatoid arthritis. Br. J. Rheumatol. 35, 781-790 (1996)
74. Sobocki, P., Pugliatti, M., Lauer, L., Kobelt, G.: Estimation of the cost of MS in Europe: extrapolations from a multinational cost study. Mult. Scler. 13, 1054-1064 (2007)